iSTAR Medical Receives European Market Approval for Glaucoma Implant MINIject

iSTAR Medical announced that its MIGS device, MINIject, has been approved in Europe for open-angle glaucoma patients. 

Data reported to date by iSTAR Medical across four trials in over 150 patients consistently show that MINIject demonstrates a balance of powerful and sustained IOP reduction with a positive safety profile. 

MINIject’s powerful efficacy and safety make it optimal for treatment in a broader glaucoma population, meaning flexibility for use in a greater number of procedures. iSTAR Medical is now rolling out MINIject commercially in select regions across Europe and is delighted that its first commercial implantations have already taken place in Germany.

"With today’s European approval, MINIject becomes the only commercially available MIGS device targeting the supraciliary space as a natural outflow pathway for IOP reduction," Michel Vanbrabant, CEO of iSTAR Medical, said in a company news release. "This is a major milestone for iSTAR Medical and our mission to bring truly next-generation MIGS devices to the glaucoma community. I want to thank our team, our investors, and our medical partners for their continued belief in a safer and better way to manage glaucoma by targeting the supraciliary space, with an implant powered by our proprietary STAR material."

Positive two-year results from iSTAR Medical’s STAR-II European trial were recently presented at the 125th American Academy of Ophthalmology (AAO) meeting in New Orleans, demonstrating a sustained powerful efficacy and safety outcome in patients with open-angle glaucoma, consistent with all MINIject trial outcomes to date.

Professor Dr. Burkhard Dick, Head of the Department of Ophthalmology at University Eye Hospital Bochum, Germany, and one of the MINIject STAR-II trial investigators, treated the first patient with MINIject after European approval. He commented: "I’m very pleased that I’m now able to offer the MINIject supraciliary device as a treatment option to my mild-to-moderate glaucoma patients, the first of which was treated successfully today. Based on results so far, MINIject may open up new treatment paradigms for patients with glaucoma across Europe."

MINIject is currently being investigated in iSTAR Medical’s pivotal STAR-V study, which was approved by the FDA in July 2021, the results of which will be instrumental to gain commercial access for MINIject in the US market. The study will enroll over 350 patients with primary open-angle glaucoma.